Wedbush Equities Analysts Lower Earnings Estimates for RCUS

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Wedbush cut their Q2 2025 earnings per share (EPS) estimates for Arcus Biosciences in a report issued on Wednesday, May 7th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($1.11) per share for the quarter, down from their prior estimate of ($1.01). Wedbush currently has a "Outperform" rating and a $33.00 target price on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. Wedbush also issued estimates for Arcus Biosciences' Q3 2025 earnings at ($1.13) EPS, Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($4.53) EPS, FY2026 earnings at ($4.32) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($0.52) EPS and FY2029 earnings at $3.37 EPS.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.12). The firm had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company's revenue was down 80.7% compared to the same quarter last year. During the same period last year, the company earned ($0.05) EPS.

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company dropped their price target on shares of Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group reduced their price objective on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. HC Wainwright raised shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. Bank of America dropped their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a report on Wednesday, February 19th. Finally, Barclays lowered their target price on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research report on Wednesday, April 23rd. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Arcus Biosciences presently has an average rating of "Moderate Buy" and an average price target of $25.67.

Arcus Biosciences Stock Down 2.2%

RCUS traded down $0.19 on Friday, hitting $8.48. 540,883 shares of the company were exchanged, compared to its average volume of 836,297. The company has a market cap of $897.90 million, a PE ratio of -2.69 and a beta of 0.88. Arcus Biosciences has a 12 month low of $6.50 and a 12 month high of $18.98. The stock's fifty day moving average is $8.35 and its 200-day moving average is $12.28. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24.

Institutional Investors Weigh In On Arcus Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Gilead Sciences Inc. purchased a new stake in shares of Arcus Biosciences in the 4th quarter worth about $447,610,000. Barclays PLC boosted its holdings in Arcus Biosciences by 49.0% in the third quarter. Barclays PLC now owns 118,693 shares of the company's stock valued at $1,816,000 after acquiring an additional 39,015 shares during the last quarter. Norges Bank acquired a new position in Arcus Biosciences during the fourth quarter valued at approximately $507,000. US Bancorp DE raised its position in Arcus Biosciences by 2,432.0% in the fourth quarter. US Bancorp DE now owns 6,887 shares of the company's stock valued at $103,000 after purchasing an additional 6,615 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in Arcus Biosciences during the 4th quarter worth approximately $207,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Arcus Biosciences

In related news, Director Yasunori Kaneko bought 20,000 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The shares were purchased at an average cost of $10.06 per share, with a total value of $201,200.00. Following the completion of the acquisition, the director now directly owns 28,400 shares in the company, valued at approximately $285,704. The trade was a 238.10% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Terry J. Rosen acquired 19,800 shares of the business's stock in a transaction on Thursday, February 27th. The shares were purchased at an average price of $10.18 per share, with a total value of $201,564.00. Following the completion of the purchase, the chief executive officer now owns 2,554,160 shares in the company, valued at $26,001,348.80. This represents a 0.78% increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.